// App-Quantinova.ai

184 : Do we need daily corticosteroid combined with docetaxel when treating against castration-resistant prostate cancer?

Researchers

Presenter

  • Tatsuya Shimomura

Principal Investigators

  • N/A

Medical Centers

  • Jikei University, Minato Ku, Tokyo, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Estramustine

  • Docetaxel

  • Methadone hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved